DDT-resistant insects have additional genetic advantage that helps resistance spread
Insects that can withstand the powerful pesticide DDT that was banned in the 1970s have an additional genetic advantage over their rivals that has helped them spread across the globe ever since, according to research published in Current Biology tomorrow (9 August 2005). This discovery overturns current theories that resistance to pesticides burdens insects with a genetic disadvantage tha...PCR Grade Deoxynucleotides Additional power to perfect your PCR experiments
Deoxynucleotides are vital components in amplification reactions, and the purityof these reagents significantly influences the results of your experiments. Roche Applied Science developed a new manufacturing and purificationprocess for...Senate Democrats strip additional Act 255 funding from budget
The caucus voted to delete provisions that would increase the maximum annual amount of...Small Tree receives additional angel funding
The company makes network drivers and other products for Ap...API Releases New Software, Acquires Additional Contracts
Healthcare organizations can increase their productivity and be more responsive to the needs of their employees and thus improve the quality of the care they provide as a result of two new products from , a Hartford, Wis.-based software company. API Software announced Tuesday the availability of the companys wireless Emp...Additional Radiotheraphy for Breast Cancer
Research says that giving extra radiotherapy to patients with early breast cancer significantly reduces the risk of cancer recurring in the breast. //The results were so clear that clinical practice should be changed immediately, particularly for younger women. Nearly five thousand patients took part in the study. The majority of patients had undergone complete removal of their tumor....Adding An Additional Drug May Help Patients With Glaucoma
Adding the drug latanoprost, also known as Xalatan, to conventional drugs used to treat the most common form of glaucoma can help reduce dangerous pressure // in the eye that leads to blindness. Researchers conducted their study among 380 patients with open-angle glaucoma or another form of glaucoma known as exfoliation glaucoma who had originally used the drug in another three-year stud...Additional Responsiblities To Be Taken Up By Allied Healthcare Professionals
In order to meet the growing demand for medical staff, it has been proposed to extend the Medicare payments to other health professionals. The role, currently played by nurses, podiatrist surgeons and other allied health professionals would be further extended to accomodate them into vacant postitions. // It has led to mixed reactions from doctors and other health professionals. The pro...No More Additional Cases of Mad Cow Disease in Canada
Mad cow disease or bovine spongiform encephalopathy (BSE) is the condition in which there is extensive wasting of the brain among the cattle. It is very fatal.// The Canadian Food Inspection Agency (CFIA) started its investigation when the fourth cow was tested positive for this disease. The cow was home-grown and six-years old. The results of the investigation were that there...NACO to Introduce 400 Additional AIDS/HIV Screening Centers
New Delhi :The National AIDS Control Organization (NACO) is due to introduce 400 additional testing centers in several States across the country mainly in the central and northern parts of India.// With the opening of the additional testing centers, the number of centers will total 1150. Nearly 5.2 million people have been found combating HIV/AIDS, according to results from the annual...Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics,Incorporated (Nasdaq: CYTK) announced results from the analyses ofthree Phase II clinical trials of ispinesib administered asmonotherapy, one in patients with hepatocellular cancer, one inpatients with melanoma, and one in patients with hormone-refractoryprostate cancer. I...Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 14, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX) today announced the presentation ofadditional data related to its immuno-inflammatory productcandidates, CRx-102 and CRx-139, at the European League AgainstRheumatism (EULAR) Annual Congress of Rheumatology meeting, June13-16, 2007 in Barcelona, Spain. In a poster entitled "Inhibition...